In conclusion, although rhIL-11 is useful for treating chemotherapy-induced thrombocytopenia, it is important to monitor the patients’ clinical status and re-examine BNP levels frequently during the use of rhIL-11. This evidence concerns the gene NPPB and Thrombocytopenia.